Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (EBRAIN-MEL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03898908
Recruitment Status : Recruiting
First Posted : April 2, 2019
Last Update Posted : December 2, 2019
Sponsor:
Collaborators:
Pierre Fabre Medicament
MFAR
Information provided by (Responsible Party):
Grupo Español Multidisciplinar de Melanoma

Brief Summary:
Phase II clinical trial, with two cohorts of patients included in parallel, all with melanoma BRAF mutated and brain metastases without previous local treatment in the brain. Cohort 1 will include patients with asymptomatic brain metastases and cohort 2 will include patients with symptomatic brain metastasis.

Condition or disease Intervention/treatment Phase
Metastatic Melanoma Brain Metastases Drug: encorafenib Drug: binimetinib Radiation: Whole brain radiation therapy Radiation: Radiosurgery/stereotactic radiosurgery Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 38 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Cohort 1 will include patients with asymptomatic brain metastases and without previous local treatment in the brain (N=48), while cohort 2 will include patients with symptomatic brain metastasis and without previous local treatment in the brain (N=15).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II, Multicentre Clinical Trial to Evaluate the Activity of Encorafenib and Binimetinib Administered Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Actual Study Start Date : July 18, 2019
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : April 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: COMBO450

Encorafenib - Orally, 75 mg and 50 mg capsules Binimetinib - Orally, 15 mg tablets

In each cohort, patients will be treated with encorafenib 450 mg once daily and binimetinib 45 mg twice daily until PD or death.

Drug: encorafenib

Encorafenib 75mg and 50mg (capsules) for a 450mg daily for oral administration during 56 days and after local radiation treatment.

If no progression of disease progression (PD) is reported, treatment will continue until PD, unacceptable toxicity or death.

Other Name: Braftovi

Drug: binimetinib
Binimetinib 15mg (tablets) for a 45mg/12 hours for oral administration during 56 days and after local radiation treatment.
Other Name: Mektovi

Radiation: Whole brain radiation therapy

The whole brain planning target volume (PTV) will receive 30 Gy in 10 fractions.

Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks.


Radiation: Radiosurgery/stereotactic radiosurgery

Dose selection must be based on previously published Radiation Therapy Oncology Group (RTOG) data, with dose modification left up to the treating physician. The total dose will depend on the size of the metastatic lesion(s) and proximity to critical structures.

Suggested doses are as follow: 1 fraction x 15-25 Gy; 3 fractions x 9-11 Gy; 5 fractions x 6-7 Gy; or 6 fractions x 5-6 Gy.

For GTV > 20 mm hypofractionated stereotactic radiotherapy could be preferred. Treatment will be delivered once daily, alternate-day, 3 fractions per week.





Primary Outcome Measures :
  1. Intracranial objective response by RECIST 1.1 before local radiotherapy treatment in cohort 1 [ Time Frame: 24 months after start of treatment ]
    iORR calculated as the proportion of patient with a best overall intracranial response of complete response (CR) or partial response (PR) before local treatment in cohort 1. The final statistical analysis of this endpoint is expected to be performed within 3 months after the local treatment of the last patient in cohort 1. This outcome will be assessed on day 56, and every 8 weeks up to 24 months after start of treatment


Secondary Outcome Measures :
  1. Intracranial objective response by RECIST 1.1 before local radiotherapy treatment in cohort 2 [ Time Frame: 24 months after start of treatment ]
    ORR calculated as the proportion of patient with a best overall intracranial response of complete response (CR) or partial response (PR) before local treatment in cohort 1. The final statistical analysis of this endpoint is expected to be performed within 3 months after the local treatment of the last patient in cohort 2. This outcome will be assessed on day 56, and every 8 weeks up to 24 months after start of treatment

  2. Global intracranial response in both cohorts [ Time Frame: 24 months ]
  3. Duration of intracranial response in both cohorts [ Time Frame: 24 months ]
  4. Duration of global response in both cohorts [ Time Frame: 24 months ]
  5. Intracranial progression-free survival (PFS) by RECIST 1.1 in both cohorts [ Time Frame: 24 months ]
  6. Global (intracranial and extracranial) progression-free survival in both cohorts [ Time Frame: 24 months ]
  7. Percentage of patients free of progression (intracraneal and extracraneal) [ Time Frame: 24 months ]
  8. Overall survival in both cohorts [ Time Frame: 24 months ]
  9. Percentage of patients alive in both cohorts [ Time Frame: 24 months ]
  10. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 until local treatment in both cohorts [ Time Frame: 24 months ]
  11. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 after local treatment in both cohorts [ Time Frame: 24 months ]
  12. Change on Quality of life at week 8 in both cohorts based on the EORTC QLQ 30 scale [ Time Frame: 8 weeks ]
    Compared to baseline evaluation evaluated after 8 weeks since the start of treatment

  13. Change on Quality of life at week 24 in both cohorts based on the EORTC QLQ 30 scale [ Time Frame: 24 weeks ]
    Compared to baseline evaluation evaluated after 24 weeks since the start of treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent of approved by the investigator's Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to the performance of any trial activities.
  • Histologically confirmed diagnosis of unresectable metastatic cutaneous melanoma, or unknown primary melanoma with one or more brain metastasis with a diameter of 10 to 50 mm, measured by contrast enhanced MRI.
  • Presence of a BRAF V600E or V600K mutation, or both, in their tumour tissue.
  • Barthel Index of Activities of Daily Living > 10.
  • Subjects aged ≥ 18 years.
  • ECOG 0-1 in asymptomatic patients (cohort 1), 0-2 in symptomatic patients (cohort 2).
  • Adequate haematological function (Haemoglobin ≥ 9 g/dL, may have been transfused; Platelet count ≥ 100 × 109/L; Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.)
  • Adequate hepatic function defined by a total bilirubin level ≤ 2.0 × the upper limit of normality (ULN) and AST and ALT levels ≤ 2.5 × ULN or AST and ALT levels ≤ 5 x ULN (for subjects with documented metastatic disease to the liver).
  • Serum Creatinine ≤ 2.0 x ULN or estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method).
  • Evidence of at least one measurable lesion as detected by radiological or photographic methods according to guidelines based on Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
  • Naïve untreated patients or patients who have progressed on or after prior first line immunotherapy for unresectable locally advanced or metastatic melanoma, but it must have ended at least 6 weeks prior to randomization; prior adjuvant therapy is permitted (e.g. IFN, IL-2 therapy, any other immunotherapy, radiotherapy or chemotherapy), BRAF or MEK inhibitors can be used in the adjuvant setting, providing the relapse does not occur during the adjuvant treatment or within 12 months after the end of it, and providing the adjuvant treatment with targeted therapy did not cause in the patient any grade 3-4 toxicity not including medically serious and reversible/controlled toxicities (ex: GGT elevation, CPK elevation, vomiting).
  • Steroids or anticonvulsants are allowed if clinically needed and are not being administered in an increasing dose.
  • Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.
  • Normal functioning of daily living activities.
  • Willingness and ability to attend scheduled visits, follow the treatment schedule and undergo clinical tests and other study procedures.

Exclusion Criteria:

  • Uveal or mucosal melanoma.
  • History of leptomeningeal metastases, with the exception that they are only seen in brain MRI and the patient has ECOG 0-1 and no neurological symptoms (except for cohort 2, where symptomatic patients will be allowed if ECOG is 0-2).
  • Another cancer in the last five years, except for in situ carcinoma of the cervix or squamous cell carcinoma of the skin adequately treated or limited basal cell skin cancer adequately controlled.
  • History of or current evidence of central serous retinopathy (CSR), retinal vein occlusion (RVO) or history of retinal degenerative disease (RDD).
  • Any previous systemic chemotherapy treatment, extensive brain radiotherapy, targeted therapy for locally advanced unresectable or metastatic melanoma; Immunotherapy treatment is allowed but must have ended at least 6 weeks prior to randomization.
  • History of Gilbert's syndrome.
  • Previous treatment with a BRAF or MEK inhibitor in metastatic setting. This treatment will be allowed in the adjuvant setting (see above). Previous treatments with immunotherapy will be allowed in both the metastatic and adjuvant setting.
  • Known positive serology for human immunodeficiency virus, or an active hepatitis B or hepatitis C infection, or both.
  • Impaired cardiovascular function or clinically significant cardiovascular diseases "Clinically significant (i.e., active) cardiovascular disease: cerebrovascular accident/stroke (< 6 months prior to enrolment), myocardial infarction (< 6 months prior to enrolment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), a LVEF < 50% evaluated by MUGA or echocardiography, or serious cardiac arrhythmia requiring medication or a triplicate average baseline QTc interval > 500 ms."
  • Uncontrolled arterial hypertension despite medical treatment.
  • Moderate (Child Pugh Class B) or severe (Child Pugh Class C) hepatic impairment.
  • Impairment of gastrointestinal function.
  • Neuromuscular disorders associated with high concentrations of creatine kinase.
  • Pregnant or nursing (lactating) women.
  • Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study.
  • Known hypersensitivity to encorafenib, binimetinib or their components.
  • Persisting toxicity related to prior therapy of Grade >1 NCI-CTCAE v 4.03; however, alopecia and sensory neuropathy Grade ≤ 2 is acceptable.
  • Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 180 days after the last dose of study treatment.
  • Known alcohol or drug abuse.
  • Inability to swallow tablets or capsules.
  • Total lactase deficiency or glucose-galactose malabsorption.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03898908


Contacts
Layout table for location contacts
Contact: Federico Nepote +34 93 434 44 12 investigacion@mfar.net

Locations
Layout table for location information
Spain
Hospital Universitario Son Espases Recruiting
Palma De Mallorca, Baleares, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Pablo Luna, M.D.         
Hospital Universitario Marqués de Valdecilla Recruiting
Santander, Cantabria, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Almudena García Castaño, M.D.         
Hospital Universitario Quirón Dexeus Recruiting
Barcelona, Cataluña, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: María González Cao, M.D.         
Complejo Hospitalario Universitario Insular de Canarias Not yet recruiting
Las Palmas de Gran Canaria, Las Palmas, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Delvys Rodríguez Abreu, M.D.         
Hospital Clínico Universitario Virgen de la Arrixaca Recruiting
El Palmar, Murcia, Spain, 30120
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Pablo Cerezuela, M.D.         
Hospital Universitari Vall d'Hebron Not yet recruiting
Barcelona, Spain, 08035
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Eva Muñoz, M.D.         
Hospital Clínic de Barcelona Recruiting
Barcelona, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Ana Arance-Fernández, M.D., Ph.D.         
Hospital del Mar Recruiting
Barcelona, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Clara Montagut, MD, PhD         
Hospital Universitario Reina Sofía Recruiting
Córdoba, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Pedro Sánchez Mauriño, M.D.         
Hospital Lucus Augusti Recruiting
Lugo, Spain, 27003
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Begoña Campos Balea, M.D.         
Hospital Universitario Ramón y Cajal Recruiting
Madrid, Spain, 28034
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Ainara Soria, MD         
H. U. Gregorio Marañón Recruiting
Madrid, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Ivan Márquez Rodas, MD         
Hospital Clínico San Carlos Not yet recruiting
Madrid, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Carlos Aguado, M.D.         
Hospital Universitario La Paz Recruiting
Madrid, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Enrique Espinosa, M.D.         
Hospital Regional Universitario de Málaga Not yet recruiting
Málaga, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Miguel Ángel Berciano, MD, PhD         
Clínica Universidad de Navarra Not yet recruiting
Pamplona, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Salvador Martín Algarra, M.D.         
Hospital Universitario Virgen Macarena Not yet recruiting
Sevilla, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Luis De la Cruz Merino, M.D.         
Hospital General Universitario de Valencia Recruiting
Valencia, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Alfonso Berrocal-Jaime, MD,PhD         
Hospital Universitario y Politécnico La Fe Not yet recruiting
Valencia, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Roberto Díaz-Beveridge, M.D., Ph.D.         
Hospital Miguel Servet Recruiting
Zaragoza, Spain
Contact: MFAR Clinical Research       investigacion@mfar.net   
Principal Investigator: Teresa Puértolas, M.D.         
Sponsors and Collaborators
Grupo Español Multidisciplinar de Melanoma
Pierre Fabre Medicament
MFAR
Investigators
Layout table for investigator information
Study Chair: Iván Márquez Rodaz, M.D. Hospital General Universitario Gregorio Marañón
Study Chair: Alfonso Berrocal Jaime, M.D. Hospital Universitario General de Valencia

Layout table for additonal information
Responsible Party: Grupo Español Multidisciplinar de Melanoma
ClinicalTrials.gov Identifier: NCT03898908     History of Changes
Other Study ID Numbers: GEM-1802
2018-002530-20 ( EudraCT Number )
First Posted: April 2, 2019    Key Record Dates
Last Update Posted: December 2, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Grupo Español Multidisciplinar de Melanoma:
metastases
melanoma
encorafenib
binimetinib
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neoplasm Metastasis
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplastic Processes
Pathologic Processes